SCHEMBL7150301

SCHEMBL7150301

COc1ccc(S(=O)(=O)Nc2cc(NC(=O)c3ccc(Cl)c(Cl)c3)ccc2OC)cc1

nearest known ligand 0.66

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.66
ALDH1A1 P00352 7/20 0.66
MAPT P10636 6/20 0.66
KMT2A Q03164 5/20 0.66
SMN1; SMN2 Q16637 5/20 0.66
MEN1 O00255 4/20 0.66
KDM4E B2RXH2 4/20 0.64
HTT P42858 2/20 0.63
CYP2C9 P11712 1/20 0.61
HPGD P15428 2/20 0.60
MAPK1 P28482 1/20 0.55
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7152089 0.92 MAPT (0.64) LMNAALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL7149932 0.84 CPT2 (0.64) LMNAALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL7150208 0.83 KMT2A (0.70) LMNAALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL7149512 0.82 ALDH1A1 (0.59) LMNAALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL7150141 0.81 MEN1 (0.57) LMNAALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL4251946 0.80 TAS1R3 (0.74) ALDH1A1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL7537988 0.78 LMNA (0.61) LMNAALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL17512436 0.78 MAPT (0.53) LMNAALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL7209352 0.78 AVPR2 (0.59) LMNAALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL12217974 0.78 TP53 (0.74) LMNAALDH1A1MAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6528528-B2 Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes WARNER-LAMBERT COMPANY 2003-03-04 US claimed
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis CONNOR DAVID THOMAS (US) 2001-10-18 US claimed
US-6528528-B2 Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis CONNOR DAVID THOMAS (US) 2001-10-18 US disclosed
US-6268387-B1 INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. WARNER-LAMBERT COMPANY 2001-07-31 US disclosed
EP-1042276-A1 THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY LLC (US) 2000-10-11 EP disclosed
WO-1999032433-A1 THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis TPMT, CTH, CBS LMNA 1617/4885ALDH1A1 369/4885MAPT 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.